Budiodarone
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
JSmol) | |
| |
|
Budiodarone (ATI-2042) is an
Creation of arrythmias
Treatment of arrhythmias
Budiodarone holds much promise as an antiarrhythmic drug to prevent fibrillation. As a drug that spans over many of antiarrhythmic drug classes, the electrophysiological activity of budiodarone includes:[4]
Inhibition of potassium, sodium and calcium channels
Through inhibiting potassium channels, budiodarone causes a decreased efflux of potassium out of the myocyte during the refractory period of its action potential, increasing the time it takes to reach the resting membrane potential.
Through blocking sodium channels, budiodarone causes a decrease in sodium influx into myocytes during the depolarization period of its action potential.
Through blocking calcium channels, budiodarone causes a decrease in calcium influx into myocytes, decreasing intracellular calcium and decreasing cardiac contractility, which is beneficial in preventing arrhythmias, but detrimental in ventricular contraction.
Increase in atrial myocyte refractory period
Through prolonging the refractory and depolarization periods of the action potential, there is a decreased likelihood that electrical re-entry will occur.
Increased stimulus-to-atrium and atrium-to-bundle of his intervals
Increasing the time interval between stimulus to atrium and/or atrium to
Increased MAPD90 and QT-intervals
Increasing the time interval of MAPD90 (response of monophasic action potential duration at 90% repolarization)in action potential conduction, slowing the rate of myocyte contraction, thereby slowing heart rate.
Dose-dependent decrease in heart rate
A decrease in heart rate reduces the risk of atrial fibrillation.
Clinical trials
Preliminary trials of budiodarone have administered the drug orally as a
There has also been evidence of prolonged budiodarone cardiac effect days after drug discontinuation as the atrial fibrillation baseline measurements were not reached in washout periods.[7] This suggests that budiodarone may promote atrial re-modelling to improve malfunctioning ion channels that once potentiated fibrillation.
Future use
Data on the effects of long-term budiodarone are not yet available. The completion of current clinical trials will examine chronic budiodarone use to confirm or deny its use as an effective and safe antiarrhythmic drug.
See also
References
- PMID 10738049.
- PMID 15872201.
- PMID 10956284.
- ^ PMID 11259553.
- CiteSeerX 10.1.1.991.2904.
- PMID 12062331.
- ^ PMID 19174378.
- ^ a b c Ezekowitz M, Hohnloser SH, Lubinski A, Bandman O, Canafax D, Ellis DJ, Milner PG, Ziola M, Thibault B (May 2009). PASCAL: a randomized doubleblind, placebo-controlled study of budiodarone (ATI-2042) in patients with paroxysmal atrial fibrillation and pacemakers with atrial fibrillation data logging capabilities. Heart Rhythm Society Annual Scientific Sessions. Boston, Mass.